benserazide has been researched along with Disease Exacerbation in 5 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prenatal treatment of Down syndrome fetuses is also suggested." | 1.51 | Mental retardation in Down syndrome: Two ways to treat. ( Kamoun, PP, 2019) |
| "Unfortunately, with disease progression, levodopa reduces Parkinsonism at the cost of evoking abnormal involuntary movements known as levodopa-induced dyskinesia (LID)." | 1.36 | Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats. ( Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamoun, PP | 1 |
| Yang, X | 1 |
| Yuan, W | 1 |
| Ren, T | 1 |
| Song, L | 1 |
| Wu, N | 1 |
| Liu, Z | 1 |
| Ishihara, A | 1 |
| Miyachi, T | 1 |
| Nakamura, T | 1 |
| Ohtsuki, T | 1 |
| Kimura, Y | 1 |
| Kihira, K | 1 |
| Yamawaki, T | 1 |
| Matsumoto, M | 1 |
| Grötzsch, H | 1 |
| Schnorf, H | 1 |
| Morris, MA | 1 |
| Moix, I | 1 |
| Horvath, J | 1 |
| Prilipko, O | 1 |
| Burkhard, PR | 1 |
| Bayülkem, K | 1 |
| Erişir, K | 1 |
| Tuncel, A | 1 |
| Bayülkem, B | 1 |
1 trial available for benserazide and Disease Exacerbation
| Article | Year |
|---|---|
A study on the effect and tolerance of lisuride on Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Disease Progression; Drug Therapy, Combinatio | 1996 |
4 other studies available for benserazide and Disease Exacerbation
| Article | Year |
|---|---|
Mental retardation in Down syndrome: Two ways to treat.
Topics: Aminooxyacetic Acid; Animals; Benserazide; Brain; Chromosomes, Human, Pair 21; Cobamides; Cystathion | 2019 |
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease | 2010 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 2011 |
Phenotypic heterogeneity of dopa-responsive dystonia in monozygotic twins.
Topics: Adult; Benserazide; Biopterins; Clubfoot; Dihydroxyphenylalanine; Disease Progression; Diseases in T | 2004 |